Skip to main
SXTP
SXTP logo

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc. demonstrates a strong outlook due to the promising results of its product Arakoda, which achieved an 80% cure rate in a clinical case series for patients with persistent babesiosis who did not respond to previous treatments. The drug's advantages, such as a convenient dosing regimen, good tolerability, and lack of drug resistance reports, position it favorably in the competitive malaria prophylaxis market. Furthermore, the initiation of the expanded access clinical study for Arakoda indicates ongoing commitment to advancing its pipeline, which could positively impact future earnings per share estimates.

Bears say

60 Degrees Pharmaceuticals Inc is facing financial strain due to the necessity of paying deferred offering costs related to its proposed offerings, which suggests a reliance on capital raising for operational liquidity. Additionally, the company operates in a highly competitive specialty pharmaceutical market, where ongoing research and development expenses may strain its financial resources without guaranteed successful outcomes. With a focus on infectious diseases, the company's pipeline may also be negatively impacted by external factors such as market competition and regulatory challenges, further contributing to a cautious financial outlook.

SXTP has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 1 analysts, SXTP has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.